Vertex Pharmaceuticals Incorporated (VRTX)
Vertex Pharmaceuticals (VRTX) Declines More Than Market: Some Information for Investors
Vertex Pharmaceuticals (VRTX) concluded the recent trading session at $435.76, signifying a -2.25% move from its prior day's close.
Got $5,000? 1 Cash-Flow King to Buy and Hold Forever That Wall Street Is Completely Mispricing
Vertex Pharmaceuticals (NASDAQ:VRTX | VRTX Price Prediction) screens as a long-duration compounder because it sits on a global monopoly in cystic fibrosis therapies that generates substantial free cash, while Wall Street prices it closer to a generic large-cap biotech than to the cash-flow compounder its financials describe.
Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know
Vertex (VRTX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Vertex Pharmaceuticals Incorporated (VRTX) Presents at Bernstein 42nd Annual Strategic Decisions Conference Transcript
Vertex Pharmaceuticals Incorporated (VRTX) Presents at Bernstein 42nd Annual Strategic Decisions Conference Transcript
Vertex Pharmaceuticals Incorporated (VRTX) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
Vertex Pharmaceuticals Incorporated (VRTX) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It
Recently, Zacks.com users have been paying close attention to Vertex (VRTX). This makes it worthwhile to examine what the stock has in store.
VRTX's Alyftrek, Journavx & Casgevy See Strong Momentum in Q1 Earnings
Vertex's new drugs are gaining momentum as Alyftrek tops $1 billion in sales and Journavx prescriptions accelerate.
Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know
Zacks.com users have recently been watching Vertex (VRTX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Vertex Pharmaceuticals Incorporated (VRTX) Q1 2026 Earnings Call Transcript
Vertex Pharmaceuticals Incorporated (VRTX) Q1 2026 Earnings Call Transcript
Vertex (VRTX) Reports Q1 Earnings: What Key Metrics Have to Say
The headline numbers for Vertex (VRTX) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Vertex Pharmaceuticals (VRTX) Q1 Earnings and Revenues Beat Estimates
Vertex Pharmaceuticals (VRTX) came out with quarterly earnings of $4.47 per share, beating the Zacks Consensus Estimate of $4.23 per share. This compares to earnings of $4.06 per share a year ago.
Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Vertex (VRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
